[ad_1]
FREMONT, Calif .– (BUSINESS WIRE) – Verseon
presented their oral drug candidates for Diabetic Macular Edema (DME) at
This week's international BIO 2019 convention in Philadelphia. These
drug candidates could become the first real alternative to the eyes
injections, the current standard treatment for millions of diabetics at
risk of vision loss.
"Our oral development candidate has the potential to redefine how the EMR is
Dr. Anirban Datta, Senior Director of Discovery at Verseon
Biology. "Not only could it replace annoying eye injections, but it
could even become the very first drug to prevent the onset of EMR.
Ultimately, we aim to halt the loss of vision before it starts. "
The EMR, one of the leading causes of blindness in adults, is a complication of diabetes.
with more than 20 million patients diagnosed worldwide. Macular edema occurs
when the fluid leaks from the damaged blood vessels and accumulates in the
Central region of the retina, process caused by chronic hypoglycemia
sugar. It is estimated that about a third of diabetics in the long term
patients are at risk of developing an EMR, a group that is expected to grow
significantly that the global diabetic population is increasing by approximately
425 million to more than 600 million over the next 25 years.
The current standard treatment for EMR consists of recurrent injections into
badociated with discomfort, infection and inflammation, and that
are only effective in about half of patients. Given the risk profile and
invasive of the administration, these drugs are not appropriate for
preventive treatment in chronic diabetics at risk. There is a big
unmet need for better drugs to treat and, ideally, prevent,
DME. Verseon's oral EMR program aims to meet this need.
To solve this problem, Verseon develops the first oral
drugs for EMR. At the BIO International Congress, Dr. Datta
presented preclinical data on the first candidate for the development of society
for clinical trials.
Verseon drug candidates target plasma kallikrein, a central mediator
of the disease that is not covered by current medications. In preclinical
studies, these compounds have demonstrated excellent oral
bioavailability and successfully inhibited the thickening of the retina and
retinal vascular leakage, two features of the EMR. This combination makes
promising candidates for a new generation of oral EMRs that
could potentially open an annual global market of $ 96 billion
treatment and prophylaxis.
About the Verseon Diabetic Macular Edema Program
Verseon has developed a new clbad of powerful and selective small molecules
Plasma inhibitors of kallikrein for the treatment of diabetic macular edema
(DME), a leading cause of adult blindness. Unlike the current
usual EMR treatments administered as a recurring eye
injections, Verseon develops drug candidates for oral dosing. Many
Principal Applicants Demonstrated Their Effectiveness in Retina Reduction
thickening and retinal vascular leakage, two hallmarks of the disease,
when it is administered orally. The company is currently preparing a first EMR
developmental candidate for Phase 1 trials.
About Verseon
Verseon Corporation (www.verseon.com,
AIM: VERS) develops disruptive life science technologies to advance
overall health. The clinical stage society uses its proprietary technology,
drug discovery computer platform to discover new drug candidates
which are unlikely to be found using conventional methods. pairing
computer platform with a complete internal chemistry and
biology, the company has built a growing pipeline of drugs
programs. Verseon currently has four active drug programs in the regions
anticoagulation (currently in phase 1), diabetic macular edema,
hereditary angioedema and oncology.
Find Verseon on Twitter and LinkedIn.
[ad_2]
Source link
